News Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 16:17:13 23/06/2025 BST			5-day change	1st Jan Change
310.85 ^USD	+0.37%		+0.62%	+32.04%

06-18	Alnylam Announces Promotion of Pushkal Garg as Executive Vice President and Chief Research and Development Officer	CI
06-09	Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09:20 AM

Federal Circuit Patent Watch: An Enabling Anticipatory Prior Art Reference Need Only Enable A Single Embodiment Of The Claim	06-19	AQ
Alnylam Announces Promotion of Pushkal Garg as Executive Vice President and Chief Research and Development Officer	06-18	CI
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer	06-18	BU
Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09:20 AM	06-09
Alnylam Gets EU Approval for RNAi Drug to Treat Transthyretin Amyloidosis With Cardiomyopathy	06-09	MT
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy	06-09	BU
Alnylam Receives European Commission Approval for AMVUTTRA®? for the Treatment of ATTR Amyloidosis with Cardiomyopathy	06-09	CI
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference	05-28	BU
Transcode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board	05-28	CI
Alnylam Issues 2024 Corporate Responsibility Report	05-20	BU
Alnylam Pharmaceuticals : 2024 REPORT	05-20	PU
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,124,217, According to a Recent SEC Filing	05-19	MT
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B	05-17	BU
Alnylam Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 11:20 AM	05-14
Part II Of MRNA Patent Wars: The Growing Legal Battles Shaping The MRNA Landscape	05-14	AQ
Alnylam Pharmaceuticals, Inc. to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the Helios-B Phase 3 Study Results at Heart Failure 2025 Congress	05-12	CI
Alnylam To Share Progress Across Its Transthyretin Amyloidosis Franchise Including Additional Analyses Of The Helios-B Phase 3 Study Results At Heart Failure 2025 Congress	05-12	RE
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress	05-12	BU
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference	05-05	BU
UBS Adjusts Alnylam Pharmaceuticals Price Target to $349 From $331, Maintains Buy Rating	05-02	MT
Alnylam Pharmaceuticals : Q1 2025 Earnings Presentation ›	05-01	PU
Alnylam Q1 Non-GAAP Net Loss Narrows, Revenue Rises	05-01	MT
Alnylam Pharmaceuticals : Q1 2025 Press Release ›	05-01	PU
Alnylam Pharmaceuticals : Q1 2025 Presentation ›	05-01	PU
Alnylam Pharmaceuticals : Q1 2025 GAAP/Non-GAAP Reconciliation ›	05-01	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Pharmaceuticals

Filters